<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Awad, Issam</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A Report from the CLEAR-IVH Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Data from studies such as the Surgical Trial in Intracerebral Hemorrhage [STICH] and Factor Seven for Acute Hemorrhagic Stroke Treatment [FAST] trial have suggested that intraventricular hemorrhage (IVH) volume is a predictor of mortality. Preclinical data suggest that intraventricular thrombolysis leads to faster ventricular clearance and better recovery. The CLEAR- IVH trial sought to follow up on these ideas in a phase 2 study, and this article gives an overview of the results and plans for a phase 3 study.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>